Editas Medicine, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2023. Editas is a clinical-stage genome-editing company and has not generated product sales revenue. Its lead clinical program is EDIT-301, being studied for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
Key financial results
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Collaboration and other R&D revenue | $5.3 million | $0.04 million | $18.1 million | $13.2 million |
| Research and development expense | $40.5 million | $41.3 million | $108.1 million | $123.0 million |
| General and administrative expense | $15.0 million | $16.2 million | $55.2 million | $52.7 million |
| Operating loss | $50.2 million | $57.5 million | $145.2 million | $162.5 million |
| Interest income, net | $5.1 million | $1.8 million | $12.5 million | $2.8 million |
| Net loss | $45.0 million | $55.7 million | $134.3 million | $159.7 million |
| Net loss per share, basic and diluted | $(0.55) | $(0.81) | $(1.81) | $(2.33) |
Revenue is collaboration/license revenue, not product revenue; the filing reports no product sales. Q3 2023 revenue primarily reflected an upfront payment under the Vor Biopharma license. Nine-month revenue growth also reflected the January 2023 sale of wholly owned oncology assets and licenses. Gross margin is not applicable as a product-sales measure and is not clearly presented.
At September 30, 2023, cash and cash equivalents were $82.5 million and marketable securities totaled $363.9 million, or $446.4 million combined. Total assets were $504.7 million, total liabilities $144.2 million, and stockholders’ equity $360.5 million. The filing reports no borrowings; liabilities primarily include lease obligations and deferred revenue. Accumulated deficit was $1.2 billion.
For the first nine months, operating cash use was $109.9 million, investing cash use was $66.6 million, and financing cash provided was $117.5 million, principally from the June stock offering. Cash, cash equivalents and restricted cash decreased $59.0 million to $86.4 million. In June, Editas issued 12.5 million shares for net proceeds of approximately $117.1 million. The company also had a $300 million ATM facility but had made no sales under it by quarter-end.
Changes versus prior comparable periods
- Nine-month net loss narrowed by $25.3 million, as operating expenses fell $12.4 million and net other income increased $8.1 million, principally from higher interest income.
- Nine-month R&D expense declined $14.9 million, mainly from lower external R&D spending after reprioritization toward EDIT-301. G&A rose $2.5 million, driven by a $10.1 million increase in professional services, partly offset by lower stock-based compensation.
- Q3 net loss narrowed by $10.7 million year over year; lower operating expenses and higher interest income contributed.
- Common shares issued and outstanding rose to 81.7 million from 68.8 million at December 31, 2022, primarily reflecting the June offering.
Outlook, operating developments and risks
- Management expects September 30 cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures into the third quarter of 2025. This is a forward-looking estimate and could prove inaccurate; the company says substantial additional capital will be required.
- Editas expects continued significant expenses and losses and does not expect to be profitable in 2023 or the foreseeable future. Future funding may require equity, debt, collaborations or licensing; equity financing could dilute shareholders.
- Through November 3, 2023, the company reported 27 patients enrolled in the RUBY SCD trial and eight in the EdiTHAL TDT trial. It expected to dose the 20th RUBY patient around January 2024 and anticipated clinical updates in December 2023 and mid-2024.
- In October 2023, the FDA granted EDIT-301 Regenerative Medicine Advanced Therapy designation for SCD. Management described early trial observations as encouraging, while noting clinical development and regulatory outcomes remain uncertain.
- A new manufacturing-space license and service agreement provides for up to $87.8 million in lease payments over 10 years; the lease was expected to commence in Q2 2024 and may be terminated with 12 months’ notice. Existing non-cancelable operating lease payments totaled $41.9 million.
- Patent priority and validity disputes and related proceedings remain a risk. Reimbursements to Broad and Harvard for patent-related expenses were $6.1 million in the first nine months of 2023; the company said the eventual commitment is substantial but not determinable.
- Other key risks include clinical-trial failure or delay, manufacturing scale-up, regulatory approval, intellectual-property protection, competition and the availability of additional financing. Management stated disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether EDIT-301 trial enrollment, safety, efficacy and clinical-update timelines progress as expected, and whether early results are sustained in larger patient groups.
- Whether cash burn and spending remain consistent with the projected runway into Q3 2025, including the impact of manufacturing expansion and the new lease.
- The timing and size of future collaboration, license, milestone or financing proceeds, and any resulting dilution or relinquishment of rights.
- Developments and potential costs or outcomes in the Broad/Harvard patent proceedings and other intellectual-property matters.
- How recurring collaboration revenue develops, given that current revenue is event-dependent and the company has no product sales.